Latest Clinical Development News

Page 13 of 57
Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.
Ada Torres
Ada Torres
22 May 2026
Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.
Ada Torres
Ada Torres
21 May 2026
Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.
Ada Torres
Ada Torres
20 May 2026
Alterity Therapeutics has showcased compelling Phase 2 data for ATH434 in Multiple System Atrophy, paving the way for a Phase 3 trial with FDA engagement targeted for mid-2026.
Ada Torres
Ada Torres
19 May 2026
Invion Limited has partnered with South Korea's SANGMYUNG Innovation to explore its Photosoft™ photodynamic therapy for wet age-related macular degeneration, addressing a large unmet medical need in ophthalmology.
Ada Torres
Ada Torres
19 May 2026
Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.
Ada Torres
Ada Torres
14 May 2026
Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.
Ada Torres
Ada Torres
13 May 2026
Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.
Ada Torres
Ada Torres
13 May 2026
Acrux Limited has raised $1.6 million through a discounted share placement, attracting strong demand and offering attaching options to investors. The funds will support Phase III trials for female testosterone and a co-development deal with an international partner.
Ada Torres
Ada Torres
11 May 2026
Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.
Ada Torres
Ada Torres
8 May 2026
Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.
Ada Torres
Ada Torres
7 May 2026
PYC Therapeutics has dosed the first patient in its Phase 1b trial of PYC-003, targeting Polycystic Kidney Disease, aiming to establish safety and efficacy markers ahead of registrational studies.
Ada Torres
Ada Torres
7 May 2026

Browse the archive

Full archive